BRPI0806392A8 - uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica - Google Patents

uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica

Info

Publication number
BRPI0806392A8
BRPI0806392A8 BRPI0806392A BRPI0806392A BRPI0806392A8 BR PI0806392 A8 BRPI0806392 A8 BR PI0806392A8 BR PI0806392 A BRPI0806392 A BR PI0806392A BR PI0806392 A BRPI0806392 A BR PI0806392A BR PI0806392 A8 BRPI0806392 A8 BR PI0806392A8
Authority
BR
Brazil
Prior art keywords
aclidinium
treatment
pharmaceutical composition
prevention method
patient
Prior art date
Application number
BRPI0806392A
Other languages
English (en)
Inventor
Beleta Supervia Jorge
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39247776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0806392(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of BRPI0806392A2 publication Critical patent/BRPI0806392A2/pt
Publication of BRPI0806392A8 publication Critical patent/BRPI0806392A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

uso de aclidínio, aclidínio, método de tratamento ou venção e composição farmacêutica a presente invenção refere-se a métodos de tratamento por inalação de uma doença ou condição respiratória em um paciente m necessidade do referido tratamento sem produzir no referido aciente os efeitos antimuscarínicos sistêmicos, compreendendo administrar ao referido paciente uma quantidade eficaz de aclidínio.
BRPI0806392A 2007-02-21 2008-01-31 uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica BRPI0806392A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90284307P 2007-02-21 2007-02-21
US60/902,843 2007-02-21
PCT/EP2008/000782 WO2008101591A1 (en) 2007-02-21 2008-01-31 Novel methods

Publications (2)

Publication Number Publication Date
BRPI0806392A2 BRPI0806392A2 (pt) 2011-09-06
BRPI0806392A8 true BRPI0806392A8 (pt) 2019-10-01

Family

ID=39247776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806392A BRPI0806392A8 (pt) 2007-02-21 2008-01-31 uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica

Country Status (31)

Country Link
US (2) US20110243924A1 (pt)
EP (1) EP2120936B1 (pt)
JP (2) JP5739616B2 (pt)
KR (2) KR20150038750A (pt)
CN (2) CN105395548A (pt)
AR (1) AR065392A1 (pt)
AT (1) ATE513547T1 (pt)
AU (1) AU2008217301B2 (pt)
BR (1) BRPI0806392A8 (pt)
CA (1) CA2678975C (pt)
CL (1) CL2008000461A1 (pt)
CO (1) CO6210814A2 (pt)
CY (1) CY1111799T1 (pt)
DK (1) DK2120936T3 (pt)
EC (1) ECSP099556A (pt)
ES (1) ES2367722T3 (pt)
HR (1) HRP20110556T1 (pt)
IL (1) IL200278A (pt)
MX (1) MX2009008825A (pt)
MY (1) MY153408A (pt)
NZ (1) NZ578473A (pt)
PE (1) PE20081789A1 (pt)
PL (1) PL2120936T3 (pt)
PT (1) PT2120936E (pt)
RU (1) RU2484821C2 (pt)
SI (1) SI2120936T1 (pt)
TW (1) TWI475994B (pt)
UA (1) UA98136C2 (pt)
UY (1) UY30901A (pt)
WO (1) WO2008101591A1 (pt)
ZA (1) ZA200904941B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ597920A (en) 2009-08-07 2014-05-30 Generics Uk Ltd Anhydrate of tiotropium bromide
WO2011095800A2 (en) * 2010-02-02 2011-08-11 Generics [Uk] Limited Analytical methods
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
EA201590030A1 (ru) * 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
CA3071377C (en) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes
WO2019023318A1 (en) 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA
WO2019023175A1 (en) 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
WO2020014072A1 (en) * 2018-07-09 2020-01-16 Gt Biopharma, Inc. Neostigmine pharmaceutical combination for treating myasthenia gravis
KR102169476B1 (ko) * 2020-05-20 2020-10-23 (주)신테카바이오 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
CN113825508A (zh) * 2020-05-20 2021-12-21 新泰克生物技术有限公司 用于预防或治疗严重急性呼吸综合征冠状病毒2感染疾病的组合物
EP4469041A4 (en) * 2022-01-28 2026-01-07 Univ Of Montreal ANTICHOLINERGIC COMPOUNDS INTENDED FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISORDERS
CN115267024B (zh) * 2022-07-31 2023-06-30 浙江知一药业有限责任公司 治疗呼吸系统疾病的药物组合物及其检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Also Published As

Publication number Publication date
CN105395548A (zh) 2016-03-16
TWI475994B (zh) 2015-03-11
JP2014062114A (ja) 2014-04-10
JP2010519261A (ja) 2010-06-03
IL200278A (en) 2015-03-31
HK1132673A1 (en) 2010-03-05
ECSP099556A (es) 2009-09-29
PL2120936T3 (pl) 2011-11-30
EP2120936B1 (en) 2011-06-22
KR20150038750A (ko) 2015-04-08
MX2009008825A (es) 2009-10-12
CN101616670A (zh) 2009-12-30
WO2008101591A1 (en) 2008-08-28
SI2120936T1 (sl) 2011-10-28
DK2120936T3 (da) 2011-09-26
IL200278A0 (en) 2010-04-29
AU2008217301A1 (en) 2008-08-28
US20110243924A1 (en) 2011-10-06
KR20090114401A (ko) 2009-11-03
AU2008217301B2 (en) 2012-10-04
AR065392A1 (es) 2009-06-03
CA2678975C (en) 2016-11-08
CA2678975A1 (en) 2008-08-28
CY1111799T1 (el) 2015-10-07
HRP20110556T1 (hr) 2011-09-30
NZ578473A (en) 2011-10-28
CO6210814A2 (es) 2010-10-20
MY153408A (en) 2015-02-13
EP2120936A1 (en) 2009-11-25
UY30901A (es) 2009-11-10
UA98136C2 (ru) 2012-04-25
JP5739616B2 (ja) 2015-06-24
BRPI0806392A2 (pt) 2011-09-06
ES2367722T3 (es) 2011-11-08
RU2009135078A (ru) 2011-03-27
TW200838520A (en) 2008-10-01
RU2484821C2 (ru) 2013-06-20
CL2008000461A1 (es) 2008-08-29
US20150093374A1 (en) 2015-04-02
ZA200904941B (en) 2011-11-30
PE20081789A1 (es) 2008-12-27
PT2120936E (pt) 2011-09-06
ATE513547T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112012001297A2 (pt) conector.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
WO2008151235A3 (en) Compositions for delivering medicaments into the lungs, uses thereof
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
EA201590933A1 (ru) Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования
BR112012000862A8 (pt) composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento
DE602007011913D1 (de) Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
WO2010068754A3 (en) Methods and compositions for delivery of medicaments to the lungs
BR112013011942A2 (pt) formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
HK1222585A1 (zh) 用於提供疼痛减轻和麻醉的二氢埃托啡
WO2009006246A8 (en) Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL